{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:42:04Z","timestamp":1794559324186,"version":"4.9.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T00:00:00Z","timestamp":1738454400000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011612","name":"Materials Research Institute, Pennsylvania State University","doi-asserted-by":"publisher","award":["NSF1531991"],"award-info":[{"award-number":["NSF1531991"]}],"id":[{"id":"10.13039\/100011612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P30 ES006694"],"award-info":[{"award-number":["P30 ES006694"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA023074"],"award-info":[{"award-number":["P30 CA023074"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007345","name":"University of Arizona Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007899","name":"University of Arizona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM147002"],"award-info":[{"award-number":["R35GM147002"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA272487"],"award-info":[{"award-number":["R01CA272487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007482","name":"Arizona State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007482","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.biomaterials.2024.122477","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T11:21:53Z","timestamp":1705663313000},"page":"122477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy"],"prefix":"10.1016","volume":"306","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2016-0517","authenticated-orcid":false,"given":"Zhiren","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8546-7384","authenticated-orcid":false,"given":"Wenpan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2403-0601","authenticated-orcid":false,"given":"Yanhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen Ba","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinha","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0766-3869","authenticated-orcid":false,"given":"Minhyeok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron James","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5877-619X","authenticated-orcid":false,"given":"Jianqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.biomaterials.2024.122477_bib1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41565-021-00950-z","article-title":"Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy","volume":"16","author":"Wang","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"15","key":"10.1016\/j.biomaterials.2024.122477_bib2","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1021\/jo000221n","article-title":"20-O-acylcamptothecin derivatives: evidence for lactone stabilization","volume":"65","author":"Zhao","year":"2000","journal-title":"J. Org. Chem."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122477_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122477_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2546","article-title":"Keeping checkpoint inhibitors in check","volume":"2","author":"Catenacci","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biomaterials.2024.122477_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1200\/EDBK_200821","article-title":"Where we stand with immunotherapy in colorectal cancer: deficient mismatch repair, proficient mismatch repair, and toxicity management","volume":"38","author":"Overman","year":"2018","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/gastro\/goz061","article-title":"Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?","volume":"8","author":"Huyghe","year":"2020","journal-title":"Gastroenterol Rep. (Oxf)"},{"key":"10.1016\/j.biomaterials.2024.122477_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jconrel.2022.07.042","article-title":"Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade","volume":"349","author":"Wang","year":"2022","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122477_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nm1196","article-title":"Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy","volume":"11","author":"Muller","year":"2005","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122477_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Contr. Release"},{"issue":"13","key":"10.1016\/j.biomaterials.2024.122477_bib10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122477_bib11","first-page":"133","article-title":"FOLFOX and FOLFIRI use in stage IV colon cancer: analysis of SEER-medicare data","volume":"18","author":"Neugut","year":"2019","journal-title":"Clin. Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122477_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122477_bib13","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel, Comput","volume":"99","author":"Zhang","year":"2010","journal-title":"Methods Programs Biomed"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib14","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1038\/s41467-018-04605-x","article-title":"Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap","volume":"9","author":"Song","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122477_bib15","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211431","article-title":"PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A-producing gammadelta T cells","volume":"220","author":"Edwards","year":"2023","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3104","article-title":"Biopolymer implants enhance the efficacy of adoptive T-cell therapy","volume":"33","author":"Stephan","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib17","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1038\/s41467-023-43079-4","article-title":"Sphingomyelin-derived nanovesicles for the delivery of the Ido1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122477_bib18","first-page":"671","article-title":"Glutathione levels in human tumors, Biomarkers : biochemical indicators of exposure, response","volume":"17","author":"Gamcsik","year":"2012","journal-title":"and susceptibility to chemicals"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib19","first-page":"307","article-title":"Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels","volume":"62","author":"Kuppusamy","year":"2002","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122477_bib20","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1039\/D0CS00718H","article-title":"Engineering nanomedicine for glutathione depletion-augmented cancer therapy","volume":"50","author":"Xiong","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"11","key":"10.1016\/j.biomaterials.2024.122477_bib21","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1021\/mp500389v","article-title":"Targeted delivery of Doxorubicin by folic acid-decorated dual functional nanocarrier","volume":"11","author":"Lu","year":"2014","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122477_bib22","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.biomaterials.2012.10.073","article-title":"PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers","volume":"34","author":"Lu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122477_bib23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jconrel.2014.10.016","article-title":"An improved D-alpha-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance","volume":"196","author":"Lu","year":"2014","journal-title":"J. Contr. Release"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122477_bib24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/13543776.2018.1441290","article-title":"A patent review of Ido1 inhibitors for cancer","volume":"28","author":"Cheong","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122477_bib25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (Ido1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"13","key":"10.1016\/j.biomaterials.2024.122477_bib26","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-Human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122477_bib29","first-page":"678","article-title":"Comparison of the therapeutic efficacy of 188Rhenium-liposomes and liposomal doxorubicin in a 4T1 murine orthotopic breast cancer model","volume":"27","author":"Liu","year":"2012","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122477_bib30","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s11605-009-0948-x","article-title":"Effective treatment of advanced colorectal cancer by rapamycin and 5-FU\/oxaliplatin monitored by TIMP-1","volume":"13","author":"Wagner","year":"2009","journal-title":"J. Gastrointest. Surg."},{"key":"10.1016\/j.biomaterials.2024.122477_bib31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3389\/fonc.2020.00586","article-title":"FOLFOX chemotherapy ameliorates CD8 T lymphocyte exhaustion and enhances checkpoint blockade efficacy in colorectal cancer","volume":"10","author":"Guan","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.biomaterials.2024.122477_bib32","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.21873\/anticanres.13860","article-title":"Combination of trabectedin with irinotecan, leucovorin and 5-fluorouracil arrests primary colorectal cancer in an imageable patient-derived orthotopic Xenograft mouse model","volume":"39","author":"Zhu","year":"2019","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122477_bib33","first-page":"403","article-title":"The combination of 5-FU, leucovorin and CPT-11 (FOLFIRI) prolongs survival through inhibition of metastasis in an orthotopic model of colon cancer","volume":"30","author":"Ishihara","year":"2010","journal-title":"Anticancer Res."},{"issue":"3_suppl","key":"10.1016\/j.biomaterials.2024.122477_bib34","article-title":"Predicting toxicities from adjuvant treatment in a population-based cohort of early colon cancer (CC) patients (pts): a strategy to improve use of curative chemotherapy","volume":"32","author":"Gresham","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.biomaterials.2024.122477_bib35","first-page":"4244","article-title":"Efficacy and toxicity of Folfoxiri for patients with metastatic colorectal cancer, open access maced","volume":"7","author":"Huy","year":"2019","journal-title":"J. Med. Sci."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122477_bib36","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10585-013-9591-8","article-title":"Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver","volume":"30","author":"Zhang","year":"2013","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib37","first-page":"1","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.biomaterials.2024.122477_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.critrevonc.2017.08.006","article-title":"Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis","volume":"118","author":"Marques","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biomaterials.2024.122477_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1477-7819-9-154","article-title":"Treatment of colorectal liver metastases","volume":"9","author":"Ismaili","year":"2011","journal-title":"World J. Surg. Oncol."},{"issue":"13","key":"10.1016\/j.biomaterials.2024.122477_bib40","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"9138","key":"10.1016\/j.biomaterials.2024.122477_bib41","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","article-title":"Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer","volume":"352","author":"Rougier","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122477_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","article-title":"Irinotecan in the treatment of colorectal cancer","volume":"32","author":"Fuchs","year":"2006","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib43","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41467-017-01651-9","article-title":"Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression","volume":"8","author":"Lu","year":"2017","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122477_bib44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"issue":"7559","key":"10.1016\/j.biomaterials.2024.122477_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biomaterials.2024.122477_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1758834010367905","article-title":"Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects","volume":"2","author":"Bastos","year":"2010","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"18","key":"10.1016\/j.biomaterials.2024.122477_bib47","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMe2300385","article-title":"Combination therapy, including bevacizumab, for advanced colorectal cancer","volume":"388","author":"Yeku","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"7899","key":"10.1016\/j.biomaterials.2024.122477_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2024.122477_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"issue":"11","key":"10.1016\/j.biomaterials.2024.122477_bib50","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/1878-0261.12797","article-title":"Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment","volume":"14","author":"Zoetemelk","year":"2020","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122477_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12052072","article-title":"Stage IV colorectal cancer management and treatment","volume":"12","author":"Hernandez Dominguez","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/1756283X08093607","article-title":"Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor","volume":"1","author":"Carethers","year":"2008","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"12","key":"10.1016\/j.biomaterials.2024.122477_bib53","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/acs.molpharmaceut.2c00701","article-title":"Camptothesome potentiates PD-L1 immune checkpoint blockade for improved metastatic triple-negative breast cancer immunochemotherapy","volume":"19","author":"Wang","year":"2022","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122477_bib54","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1124\/jpet.106.101154","article-title":"A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system","volume":"317","author":"Wong","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122477_bib55","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.bbamem.2016.04.014","article-title":"Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes","volume":"1858","author":"Li","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.biomaterials.2024.122477_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092058","article-title":"Nanomedicine to overcome multidrug resistance mechanisms in colon and pancreatic cancer: recent progress","volume":"13","author":"Ortiz","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2024.122477_bib57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biomaterials.2016.11.013","article-title":"Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate","volume":"115","author":"Sivak","year":"2017","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib58","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1038\/s41467-021-22407-6","article-title":"Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122477_bib59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/asia.200800290","article-title":"Inorganic metal hydroxide nanoparticles for targeted cellular uptake through clathrin-mediated endocytosis","volume":"4","author":"Oh","year":"2009","journal-title":"Chem. Asian J."},{"key":"10.1016\/j.biomaterials.2024.122477_bib60","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2024.122477_bib61","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","article-title":"Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin","volume":"391","author":"Dicko","year":"2010","journal-title":"Int. J. Pharm."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224000115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224000115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:05:52Z","timestamp":1777485952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224000115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":61,"alternative-id":["S0142961224000115"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122477","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122477"}}